[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364133-105":59,"doc-detail-364133-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","screening-of-molecular-biomarkers-aspn-and-lbh-and-construction-of-a-prediction-nomogram-for-the-progression-of-esophagogastric-junction-adenocarcinoma","Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma","","Esophagogastric junction adenocarcinoma (EGJA) is a highly aggressive malignancy with poor prognosis, where early diagnosis and prediction of tumor progression remain difficult. This study identifies differentially expressed genes from TCGA, then validates ASPN and LBH at the mRNA and protein levels using qRT-PCR and immunohistochemistry in tumor versus adjacent non-tumor tissues. Clinical and pathological features were integrated into a nomogram, evaluated with ROC curves and decision curve analysis to support individualized prognostic assessment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-of-molecular-biomarkers-aspn-and-lbh-and-construction-of-a-prediction-nomogram-for-the-progression-of-esophagogastric-junction-adenocarcinoma/364133/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-of-molecular-biomarkers-aspn-and-lbh-and-construction-of-a-prediction-nomogram-for-the-progression-of-esophagogastric-junction-adenocarcinoma/364133.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which molecular biomarkers were investigated for EGJA progression?","Question",{"text":112,"@type":113},"The study investigated ASPN and LBH as stage-associated molecular biomarkers for EGJA progression and prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ASPN and LBH expressions validated?",{"text":117,"@type":113},"Differentially expressed genes were screened using TCGA, followed by qRT-PCR. Protein expression was validated by immunohistochemistry in tumor tissues and adjacent non-tumor tissues.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the nomogram predict and how was it evaluated?",{"text":121,"@type":113},"The nomogram integrates clinical and pathological features and biomarker expression to predict tumor progression, distinguishing early versus advanced stage disease. Performance was assessed using ROC curves and decision curve analysis (DCA), with an AUC of 0.977 reported for strong discrimination.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364133,1790231304,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Article  \nScreening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma  \nYe Chen1, Liuhong Yuan2, Huihui Sun1, Ying Chen1, Bo Li1, Meng Qian1, Zhenxiang Wang1, Yan Zhang1, Jie Xiong1, Qian Liang1, Kun Tao2, Zhenyu Tan2, Shuchang Xu1  \n1Department of Gastroenterology, Tongji Institute of Digestive Disease, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China; 2Department of Pathology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China  \nContributions: (I) Conception and design: Y Chen; (II) Administrative support: S Xu; (III) Provision of study materials or patients: L Yuan, K Tao, Z Tan; (IV) Collection and assembly of data: H Sun, Y Chen, B Li, M Qian, Z Wang, Y Zhang, J Xiong, Q Liang; (V) Data analysis and interpretation: Y Chen, L Yuan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Shuchang Xu, PhD. Department of Gastroenterology, Tongji Institute of Digestive Disease, Tongji Hospital, School of Medicine, Tongji University, No. 389, Xincun Road, Putuo District, Shanghai 200065, [China. Email: xschang@163.com](China. Email: xschang@163.com).  \nBackground: Esophagogastric junction adenocarcinoma (EGJA) is an aggressive malignancy of the digestive system with poor prognosis. Early diagnosis and accurate prediction of tumor progression remain major clinical challenges. This study aimed to identify and validate molecular biomarkers and construct a  \nprecise diagnostic model, providing a scientific basis for individualized treatment.  \nMethods: Differentially expressed genes (DEGs) associated with EGJA were identified using The Cancer Genome Atlas (TCGA) database. Quantitative real-time polymerase chain reaction (qRT-PCR) was then performed for further screening. The protein expression levels of ASPN and LBH were validated by immunohistochemistry in both tumor and adjacent non-tumor tissues. A nomogram was constructed by integrating clinical and pathological features, and its performance and clinical utility were assessed using  \nreceiver operating characteristic (ROC) curves and decision curve analysis (DCA) .  \nResults: Immunohistochemistry demonstrated that the protein expression of ASPN was significantly upregulated in tumor tissues, with expression levels increasing with tumor stage. Conversely, LBH was downregulated in tumor tissues and decreased with advancing stages. The predictive model achieved an area under the curve (AUC) value of 0.977, indicating excellent diagnostic and prognostic performance. DCA  \nconfirmed the clinical net benefit of the model.  \nConclusions: ASPN and LBH are critical molecular biomarkers for EGJA. The nomogram combining these two markers enables accurate distinction between early and advanced-stage tumors, offering significant  \nsupport for early diagnosis of EGJA.  \nKeywords: Esophagogastric junction adenocarcinoma (EGJA); ASPN; LBH; nomogram model; tumor  \nprogression prediction  \nSubmitted Apr 04, 2026. Accepted for publication Jun 04, 2026. Published online Jun 26, 2026.  \ndoi: 10.21037/jgo-2026-0361  \nView this article at: [https://dx.doi.org/10.21037/jgo-2026-0361](https://dx.doi.org/10.21037/jgo-2026-0361)  \nIntroduction  \nEsophagogastric junction adenocarcinoma (EGJA) is a malignant tumor of the gastrointestinal tract with high incidence and aggressive behavior. In recent years, its  \nincidence has shown a significant upward trend globally (1,2) . Due to its unique anatomical location and complex biological characteristics, the diagnosis and treatment of EGJA remain formidable challenges (3) . Tumor staging  \n© AME Publishing Company. J Gastrointest Oncol 2026;17(4):212 | [https://dx.doi.org/10.21037/jgo-2026-0361](https://dx.doi.org/10.21037/jgo-2026-0361)  \nPage 2 of 16 Chen et al. Molecular biomarkers ASPN and LBH in EGJA prognosis  \nat the time of diagnosis, the selection of individu","cbCaifYUAaKTBUos","https://ap.wps.com/l/cbCaifYUAaKTBUos","pdf",2943966,16,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Highlight box\n## Key findings\n## What is known and what is new?","[{\"question\":\"Which molecular biomarkers were investigated for EGJA progression?\",\"answer\":\"The study investigated ASPN and LBH as stage-associated molecular biomarkers for EGJA progression and prognosis.\"},{\"question\":\"How were ASPN and LBH expressions validated?\",\"answer\":\"Differentially expressed genes were screened using TCGA, followed by qRT-PCR. Protein expression was validated by immunohistochemistry in tumor tissues and adjacent non-tumor tissues.\"},{\"question\":\"What does the nomogram predict and how was it evaluated?\",\"answer\":\"The nomogram integrates clinical and pathological features and biomarker expression to predict tumor progression, distinguishing early versus advanced stage disease. Performance was assessed using ROC curves and decision curve analysis (DCA), with an AUC of 0.977 reported for strong discrimination.\"}]","Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma | PDF",1790155878,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5854f139aa99e9a78142398d2aede1a5.webp",983,1287,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38ba4e90f5968723d1d4d5092a3a2938.webp",982,1286,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/359d505ac9079e405fe0ee24558dd294.webp",981,1284,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d45b1e2dcefe6b91752ef7807b5fbb7b.webp",980,1283]